U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis; INREBIC provides new, once-daily oral option for patients affected by rare bone marrow cancer

Press/Media: Press / Media

PeriodAug 16 2019

Media coverage

2

Media coverage

  • TitleU.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis; INREBIC provides new, once-daily oral option for patients affected by rare bone marrow cancer
    Media name/outletBusiness Wire
    CountryUnited States
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis; INREBIC provides new, once-daily oral option for patients affected by rare bone marrow cancer
    Media name/outletBusiness Wire
    CountryUnited States
    Date8/16/19
    PersonsRuben Mesa